Library, Research and Evidence Based Practice: CCC publication: Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Friday, 29 May 2020

CCC publication: Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Citation: European Journal of Cancer. 2020, 134, 62-74
Author: Patrick Schöffski, Olivier Mir, Bernd Kasper, Zsuzsanna Papai, Jean-Yves Blay, Antoine Italiano, Charlotte Benson, Katerina Kopeckova, Nasim Ali, Palma Dileo, Axel LeCesne, Franka Menge, Sophie Cousin, Eva Wardelmann, Agnieszka Wozniak, Sandrine Marreaud, Saskia Litiere, Facundo Zaffaroni, Axelle Nzokirantevye, Isabelle Vanden Bempt, Hans Gelderblom